rat's nest Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : rat's nest

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: AugustWest who started this subject	6/14/2004 6:45:21 AM
From: AugustWest	of 844

Roche corrects Tarceva lung cancer data ZURICH, June 14 (Reuters) - Roche <ROG.VX> has corrected the average survival time in a study for lung cancer patients who have smoked using its drug Tarceva to 5.5 months from 3.5 months originally presented to analysts, the healthcare group said. Those patients who have smoked and took a placebo survived on average for 4.6 months, the study found. Concerns that the data originally presented June 7 at the American Society of Clinical Oncology (ASCO) indicated that lung cancer patients who have smoked using Tarceva died quicker than those on a placebo put Roche stock under pressure last week. "During the analyst briefing on Monday 7th, an error with regards to survival benefit in patient subsets was presented. This was amended," Roche said in a statement to investors on June 9 and obtained by Reuters on Monday. ((Editing by Steven Silber; Zurich newsroom +41 1 631 7340, fax 41 1 251 0476, zurich.newsroom@news.reuters.com)) REUTERS * end of story *

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next